Inventor · disambiguated record
Shuqian Jing
Also filed as: JING SHUQIAN
19 granted patents·30 pending applications·381 citations·filing 1995–2020
94Inventor score
Top patents by PatentIndex Score
49 records- 0196US7611857B2IL-receptor like molecules and uses thereofAMGEN INC·Filed 2005·Granted Nov 3, 2009·58 cites·9 claims
- 0295US7094566B2IL-17 receptor like molecules and uses thereofAMGEN INC·Filed 2001·Granted Aug 22, 2006·73 cites·26 claims
- 0395US5981245AEPH-like receptor protein tyrosine kinasesAMGEN INC·Filed 1995·Granted Nov 9, 1999·178 cites·10 claims
- 0480US10869927B2Human endothelin receptor antibody and use thereofGMAX BIOPHARM LLC·Filed 2019·Granted Dec 22, 2020·1 cites·9 claims
- 0579US10253103B2Antibody specifically binding to GLP-1R and fusion protein thereof with GLP-1GMAX BIOPHARM LLC·Filed 2018·Granted Apr 9, 2019·2 cites·31 claims
- 0678US10376581B2Human endothelin receptor antibody and use thereofGMAX BIOPHARM LLC·Filed 2016·Granted Aug 13, 2019·2 cites·10 claims
- 0777US7943738B2IL-17 receptor like molecules and uses thereofAMGEN INC·Filed 2009·Granted May 17, 2011·2 cites·7 claims
- 0876US11780916B2GIPR antibody and GLP-1 fusion protein thereof, and pharmaceutical composition and application thereofGMAX BIOPHARM LLC·Filed 2019·Granted Oct 10, 2023·1 cites·27 claims
- 0972US6455277B1Polynucleotides encoding human glial cell line-derived neurotrophic factor receptor polypeptidesAMGEN INC·Filed 1997·Granted Sep 24, 2002·26 cites·11 claims
- 1070US11712470B2Human endothelin receptor antibody and use thereofGMAX BIOPHARM LLC·Filed 2020·Granted Aug 1, 2023·0 cites·9 claims
- 1170US10059773B2Antibody specifically binding to GLP-1 R and fusion protein thereof with GLP-1GMAX BIOPHARM LLC·Filed 2014·Granted Aug 28, 2018·1 cites·17 claims
- 1268US5981246ANucleic acids encoding EPH-like receptor protein tyrosine kinasesAMGEN INC·Filed 1996·Granted Nov 9, 1999·21 cites·15 claims
- 1362US2014037635A1Methods of treatment using il-17e antagonistsAMGEN INC·Filed 2013·Application pending·0 cites
- 1461US2007123459A1IL-17 like molecules and uses thereofAMGEN INC·Filed 2006·Application pending·0 cites
- 1560US2004235714A1Neurotrophic factor receptorsAMGEN INC·Filed 2004·Application pending·0 cites
- 1658US2005048029A1Il-17 like molecules and uses thereofAMGEN INC·Filed 2004·Application pending·0 cites
- 1757US2005074427A1IL-17 like molecules and uses thereofFiled 2004·Application pending·0 cites
- 1857US2007065868A1IL-17 receptor like molecules and uses thereofAMGEN INC·Filed 2006·Application pending·0 cites
- 1957US2005003451A1IL-17 like molecules and uses thereofFiled 2004·Application pending·0 cites
- 2055US2011160438A1Il-17 receptor like molecules and uses thereofAMGEN INC·Filed 2010·Application pending·0 cites
- 2155US2010303820A1Methods of treatment using il-17e antagonistsAMGEN INC·Filed 2010·Application pending·0 cites
- 2254US2006166325A1Glial cell line-derived neurotrophic factor receptorAMGEN INC·Filed 2006·Application pending·0 cites
- 2353US11542336B2GCGR antibody and GLP-1 fusion protein thereof, pharmaceutical composition thereof and application thereofGMAX BIOPHARM LLC·Filed 2019·Granted Jan 3, 2023·0 cites·7 claims
- 2453US7531321B2Fibroblast growth factor-like molecules and uses thereofAMGEN INC·Filed 2004·Granted May 12, 2009·0 cites·8 claims
- 2552US7138251B1Polynucleotides encoding a neurotrophic factor receptorAMGEN INC·Filed 1997·Granted Nov 21, 2006·12 cites·11 claims
- 2652US2004048338A1IL-17 receptor like molecules and uses thereofFiled 2003·Application pending·0 cites
- 2752US2022411520A1Gipr antibody and fusion protein between same and glp-1, and pharmaceutical composition and application thereofGMAX BIOPHARM LLC·Filed 2020·Application pending·0 cites
- 2851US12473369B2Fusion protein of anti-eta antibody and tgf-beta trap and pharmaceutical composition and application thereof in method of treatmentGMAX BIOPHARM LLC·Filed 2020·Granted Nov 18, 2025·0 cites·19 claims
- 2951US2006216287A1EPH-like receptor protein tyrosine kinasesAMGEN INC·Filed 2005·Application pending·0 cites
- 3051US2006281149A1Transforming growth factor-beta-related molecules and uses thereofAMGEN INC·Filed 2006·Application pending·0 cites
- 3149US2002037557A1Fibroblast growth factor-like molecules and uses thereofAMGEN INC·Filed 2001·Application pending·0 cites
- 3249US2019134196A1Etar antibody, and pharmaceutical compositions and use thereofGMAX BIOPHARM LLC·Filed 2017·Application pending·0 cites
- 3349US2003124092A1IL-17 like molecules and uses thereoflike molecules and uses thereofFiled 2001·Application pending·0 cites
- 3449US2003099980A1IL-17 receptor like molecules and uses thereofFiled 2002·Application pending·0 cites
- 3549US2003175876A1Glial cell line-derived neurotrophic factor receptorAMGEN INC·Filed 2002·Application pending·0 cites
- 3647US2002045213A1IL-17 receptor like molecules and uses thereofFiled 2001·Application pending·0 cites
- 3746US12221488B2APJ antibody, fusion protein thereof with Elabela, and pharmaceutical compositions and use thereofus01GMAX BIOPHARM LLC·Filed 2019·Granted Feb 11, 2025·0 cites·12 claims
- 3846US2003166069A1Interleukin-1 receptor antagonist-like molecules and uses thereofAMGEN INC·Filed 2002·Application pending·0 cites
- 3946US2004023335A1IL-17 like molecules and uses thereofFiled 2002·Application pending·0 cites
- 4045US2002151695A1Transforming growth factor-beta-related molecules and uses thereofFiled 2001·Application pending·0 cites
- 4145US2006024267A1TNFr/OPG-like molecules and uses thereofWELCHER ANDREW A·Filed 2005·Application pending·0 cites
- 4245US2003228606A1Her-2 receptor tyrosine kinase molecules and uses thereofAMGEN INC A CORP OF THE STATE·Filed 2003·Application pending·0 cites
- 4344US2003077246A1TNFr/OPG-like molecules and uses thereofFiled 2002·Application pending·0 cites
- 4443US2006211022A1Detection of compounds that affect therapeutic activityAMGEN INC·Filed 2006·Application pending·0 cites
- 4542US2004208872A1Nucleic encoding interleukin-1 receptor antagonist-like proteins and uses thereofAMGEN INC A CORP OF THE STATE·Filed 2003·Application pending·0 cites
- 4641US2005123512A1Nucleic encoding interleukin-1 receptor antagonist-like proteins and uses thereofAMGEN INC A CORP OF THE STATE·Filed 2003·Application pending·0 cites
- 4738US2002037524A1IL-17 like molecules and uses thereofFiled 2001·Application pending·0 cites
- 4837US6992175B1Nucleic acids encoding Eph-like receptor tyrosine kinasesAMGEN INC·Filed 1999·Granted Jan 31, 2006·4 cites·8 claims
- 4935US10485870B2Stable pharmaceutical solution formulation of GLP-1R antibody fusion proteinGMAX BIOPHARM LLC·Filed 2016·Granted Nov 26, 2019·0 cites·21 claims
Join the waitlist — get patent alerts
Get an alert when Shuqian Jing files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →